Evidence map›Paper›PMID 26620888›Full record

ReviewInternational journal of obesity (2005)2016

Anorexia-cachexia and obesity treatment may be two sides of the same coin: role of the TGF-b superfamily cytokine MIC-1/GDF15.

V W W Tsai, S Lin, D A Brown, A Salis, S N Breit

Open access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in International journal of obesity (2005), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 3 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 3 syntheses or guidelines pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Proximate and ultimate causes of pregnancy sickness.Evolution, medicine, and public health · 2025
    Review
  12. Article
  13. Article
  14. TheInternational journal of molecular sciences · 2024
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Overview of growth differentiation factor 15 in metabolic syndrome.Journal of cellular and molecular medicine · 2023
    Review
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

V W W TsaiSt Vincent's Centre for Applied Medical Research, St Vincent's Hospital Sydney, Sydney, New South Wales, Australia.
S LinThe Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
D A BrownSt Vincent's Centre for Applied Medical Research, St Vincent's Hospital Sydney, Sydney, New South Wales, Australia.
A SalisThe Boden Institute of Obesity, Nutrition, Exercise & Eating Disorders, The University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0001-9176-1574
S N BreitSt Vincent's Centre for Applied Medical Research, St Vincent's Hospital Sydney, Sydney, New South Wales, Australia.
UNSW Sydney · AUGarvan Institute of Medical Research · AUThe University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anorexia-cachexia associated with cancer and other diseases is a common and often fatal condition representing a large area of unmet medical need. It occurs most commonly in advanced cancer and is probably a consequence of molecules released by tumour cells, or tumour-associated interstitial or immune cells. These may then act directly on muscle to cause atrophy and/or may cause anorexia, which then leads to loss of both fat and lean mass. Although the aetiological triggers for this syndrome are not well characterized, recent data suggest that MIC-1/GDF15, a transforming growth factor-beta superfamily cytokine produced in large amounts by cancer cells and as a part of other disease processes, may be an important trigger. This cytokine acts on feeding centres in the hypothalamus and brainstem to cause anorexia leading to loss of lean and fat mass and eventually cachexia. In animal studies, the circulating concentrations of MIC-1/GDF15 required to cause this syndrome are similar to those seen in patients with advanced cancer, and at least some epidemiological studies support an association between MIC-1/GDF15 serum levels and measures of nutrition. This article will discuss its mechanisms of central appetite regulation, and the available data linking this action to anorexia-cachexia syndromes that suggest it is a potential target for therapy of cancer anorexia-cachexia and conversely may also be useful for the treatment of severe obesity.

Indexed as

Molecular Targeted TherapyAnimalsAnorexiaAppetiteBiomarkersCachexiaEnergy MetabolismGene Expression Regulation, NeoplasticGrowth Differentiation Factor 15HumansNeoplasmsObesityTransforming Growth Factor beta1Weight GainBiomarkersGDF15 protein, humanGrowth Differentiation Factor 15TGFB1 protein, humanTransforming Growth Factor beta1

Identifiers

PMID26620888
OpenAlexW2234960724

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.